Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix

Phase 3

Recruiting

Conditions: Carcinoma Cervix,Stage III

Interventions: Drug: Nelfinavir
Drug: Cisplatin
Radiation: Pelvic EBRT and Brachytherapy

First Posted Date: 2017-08-22

Last Posted Date: 2024-04-11

Lead Sponsor: Tata Memorial Hospital

Target Recruit Count: 348

Registration Number: NCT03256916

Locations: 🇮🇳
Tata Memorial Centre, Mumbai, Maharashtra, India

Radiation Therapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia in Advanced Cervical Cancer

Not Applicable

Recruiting

Conditions: Cervical Cancer

Interventions: Radiation: Radiation
Radiation: brachytherapy
Drug: Cisplatin
Other: Hyperthermia

First Posted Date: 2017-08-15

Last Posted Date: 2017-08-15

Lead Sponsor: University of Erlangen-Nürnberg Medical School

Target Recruit Count: 999

Registration Number: NCT03249519

Locations: 🇩🇪
Universitätsklinikum Erlangen, Strahlenklinik, Erlangen, Germany

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Phase 1

Active, not recruiting

Conditions: Biphasic Mesothelioma
Epithelioid Mesothelioma
Stage I Pleural Malignant Mesothelioma AJCC v7
Stage IA Pleural Malignant Mesothelioma AJCC v7
Stage IB Pleural Malignant Mesothelioma AJCC v7
Stage II Pleural Malignant Mesothelioma AJCC v7
Stage III Pleural Malignant Mesothelioma AJCC v7

Interventions: Drug: Atezolizumab
Drug: Cisplatin
Procedure: Extrapleural Pneumonectomy
Drug: Pemetrexed Disodium
Procedure: Pleurectomy
Radiation: Radiation Therapy

First Posted Date: 2017-07-25

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT03228537

Locations: 🇺🇸
Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸
Centralia Oncology Clinic, Centralia, Illinois, United States
🇺🇸
Carle at The Riverfront, Danville, Illinois, United States

and more 176 locations

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

Phase 3

Active, not recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: Placebo
Biological: Pembrolizumab
Drug: Cisplatin
Drug: Docetaxel
Drug: Capecitabine
Drug: Oxaliplatin
Drug: 5-fluorouracil
Drug: Leucovorin

First Posted Date: 2017-07-18

Last Posted Date: 2024-10-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1007

Registration Number: NCT03221426

Locations: 🇺🇸
Fox Chase Cancer Center ( Site 0006), Philadelphia, Pennsylvania, United States
🇨🇦
Cross Cancer Institute ( Site 0033), Edmonton, Alberta, Canada
🇨🇦
Jewish General Hospital ( Site 0034), Montreal, Quebec, Canada

and more 168 locations

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2017-07-12

Last Posted Date: 2024-12-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 719

Registration Number: NCT03215706

Locations: 🇺🇸
Local Institution - 0091, Wichita, Kansas, United States
🇺🇸
Local Institution - 0004, Lexington, Kentucky, United States
🇦🇺
Local Institution - 0086, Gosford, New South Wales, Australia

and more 113 locations

Investigating Cardiovascular Adverse Events Related to Cancer Treatment

Recruiting

Conditions: Cardiovascular Morbidity
Toxicity Due to Chemotherapy
Cancer, Treatment-Related

Interventions: Drug: Anthracyclines
Drug: Trastuzumab
Drug: Bleomycin
Drug: Cisplatin

First Posted Date: 2017-06-26

Last Posted Date: 2024-05-17

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 48

Registration Number: NCT03199300

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1

Withdrawn

Conditions: Urothelial Carcinoma

Interventions: Biological: avelumab
Biological: bevacizumab
Drug: capecitabine
Drug: cisplatin
Drug: cyclophosphamide
Drug: 5Fluorouracil (5-FU)
Drug: fulvestrant
Drug: leucovorin
Drug: nab-paclitaxel
Drug: Lovaza
Radiation: Stereotactic Body Radiation Therapy
Biological: ALT-803
Biological: ETBX-011
Biological: ETBX-021
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-4000
Biological: GI-6207
Biological: GI-6301
Biological: haNK

First Posted Date: 2017-06-23

Last Posted Date: 2021-03-18

Lead Sponsor: ImmunityBio, Inc.

Registration Number: NCT03197571

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

Phase 3

Completed

Conditions: Esophageal Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Placebo
Drug: Cisplatin
Drug: 5-FU

First Posted Date: 2017-06-16

Last Posted Date: 2024-10-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 749

Registration Number: NCT03189719

Locations: 🇿🇦
The Medical Oncology Centre of Rosebank ( Site 2506), Johannesburg, Gauteng, South Africa
🇪🇸
Hospital Universitario Central de Asturias ( Site 0708), Oviedo, Asturias, Spain
🇺🇸
University of Maryland Medical Center ( Site 0013), Baltimore, Maryland, United States

and more 186 locations

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Alectinib
Drug: Entrectinib
Drug: Atezolizumab
Drug: Divarasib
Drug: Cisplatin
Drug: Pemetrexed
Drug: Docetaxel
Drug: Cobimetinib
Drug: Gemcitabine
Drug: Carboplatin
Drug: Vemurafenib
Drug: Bevacizumab

First Posted Date: 2017-06-07

Last Posted Date: 2024-11-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1000

Registration Number: NCT03178552

Locations: 🇺🇸
UC Davis; Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States

and more 174 locations

Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma

Not Applicable

Completed

Conditions: Drug-Related Side Effects and Adverse Reactions

Interventions: Drug: Docetaxel
Drug: Cisplatin

First Posted Date: 2017-06-06

Last Posted Date: 2020-02-07

Lead Sponsor: Luo yanrong

Target Recruit Count: 150

Registration Number: NCT03177174

Locations: 🇨🇳
Chinese PLA general hospital, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy